Blacklisting Is Civil Death: Supreme Court Quashes Blacklisting and Debarment of Drug Supplier Over NSQ Reports as Mandatory Retesting Under Tender Was Never Done
In M/s JPEE Drugs v. State of Madhya Pradesh & Ors., 2026 INSC 1143, a three-judge Bench of the Supreme Court quashed a three-year blacklisting of a drug supplier and a two-year debarment of one of its products, along with recovery orders, imposed by the MP Public Health Services Corporation after batches of Ascorbic Acid and Ethambutol were declared not of standard quality (NSQ). The tender required a second sample from the same batch to be tested at another laboratory before any blacklisting. That was never done. The High Court had found the breach but made quashing depend on a fresh test; the Supreme Court held that, with the batches now expired, the loss of the retesting opportunity caused by the State voided the penalty.
Key Takeaways
- Blacklisting has punitive, civil-death consequences and demands strict compliance with procedure.
- Clause 6 of Annexure IX of the tender required retesting of a second sample at another laboratory before blacklisting.
- Orders were passed on 30 September 2024, the very day the supplier filed its reply, citing no reply.
- Once the High Court found the clause breached, it should have quashed the orders, not made relief contingent on retesting.
- Retesting was never carried out and the batches have expired; the State’s delay cannot prejudice the supplier.
- The Court relied on Medipol, Medicamen Biotech, Laborate and Section 25 of the Drugs and Cosmetics Act.
Case Details at a Glance
| Case title | M/s JPEE Drugs v. State of Madhya Pradesh & Ors. |
|---|---|
| Citation | 2026 INSC 1143 (Reportable) |
| Case number | Civil Appeals arising from SLP (C) Nos. 14499-14500 of 2026 |
| Bench | Justice Vikram Nath, Justice Sandeep Mehta and Justice Augustine George Masih |
| Authored by | Justice Sandeep Mehta |
| Date of judgment | 6 October 2026 |
| Impugned orders | MP High Court at Jabalpur, 27 October 2025 in WP No. 31343 of 2024, and review order of 12 February 2026 |
| Result | Blacklisting, debarment and recovery orders quashed |
Facts of the Case
The appellant supplied drugs to government hospitals under rate contracts with MPPHSCL. Three batches of Ascorbic Acid 500 mg and one batch of Ethambutol 400 mg were reported NSQ. A show cause notice of 23 September 2024 gave seven days. The appellant replied on 30 September 2024, but orders were passed the same day: two-year debarment of Ethambutol with recovery of Rs 3,47,375, and three-year blacklisting with recovery of Rs 6,77,219. A further order on 1 October 2024 rejected the reply. The High Court directed fresh samples to be sent to a Central Government laboratory within 15 days, but retesting never happened.
Issues Before the Supreme Court
- Could the supplier be blacklisted without retesting under the tender?
- Was the High Court right to make relief contingent on retesting?
Mandatory retesting
The tender provided a two-stage process: an NSQ report, followed by retesting of a second sample from the same batch at another laboratory, with the Government laboratory’s report final. Blacklisting could follow only on confirmation. Skipping this step was fatal.
Lost opportunity
Under Sections 25(3) and 25(4) of the Drugs and Cosmetics Act and the cited precedents, where the opportunity to retest is lost because of the authorities’ delay, the adverse report cannot be acted on. With the batches expired and the rate contracts over, no retesting was possible.
Final Decision
Appeals allowed. The orders of 30 September 2024 and 1 October 2024 are quashed, and the High Court orders are set aside to that extent.
Precedents Relied On
| Case | Principle applied |
|---|---|
| Medipol Pharmaceutical v. PGIMER, (2021) 11 SCC 339 | Retesting before adverse action |
| Medicamen Biotech v. Rubina Bose, (2008) 7 SCC 196 | Loss of retesting right |
| Laborate Pharmaceuticals v. State of TN, (2018) 15 SCC 93 | Retesting and prosecution |
Analysis and Practical Points
For suppliers and procurement agencies:
- Agencies: follow tender testing protocols before blacklisting, and decide only after considering replies.
- Suppliers: insist promptly on retesting while batches are within shelf life.
- Courts: once procedural breach is found, quash rather than remit to an impossible exercise.
Frequently Asked Questions
Why was the blacklisting quashed?
Because the mandatory retesting of a second sample under the tender was never done, and the batches have since expired.
What is the effect of blacklisting?
The Court described it as civil death, with punitive consequences demanding strict procedure.
What did the High Court do?
It found the breach but made quashing depend on fresh testing, which never happened.
Which statute was relevant?
Sections 25(3) and 25(4) of the Drugs and Cosmetics Act, 1940.
Were the recovery orders also quashed?
Yes, the orders of 30 September and 1 October 2024, including recoveries, were quashed.
This article is for general information only and does not constitute legal advice. Readers should refer to the certified copy of the judgment and consult a qualified professional before acting. See our Editorial Policy and Disclaimer.
